Understanding and targeting the Rho kinase pathway in erectile dysfunction

Nature Reviews Urology

Volumn 11, Issue 11, 2014, Pages 622-628

  Sopko, Nikolai A ^a   Hannan, Johanna L ^a   Bivalacqua, Trinity J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ATORVASTATIN; CALCIUM; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FASUDIL; METHYLENE BLUE; MYOSIN LIGHT CHAIN KINASE; MYOSIN LIGHT CHAIN PHOSPHATASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA RHO ASSOCIATED PROTEIN KINASE; TESTOSTERONE; UNCLASSIFIED DRUG; ENZYME INHIBITOR;

AGING; APOPTOSIS; AUTOPHOSPHORYLATION; BRAIN VASOSPASM; COMPREHENSION; CONFORMATIONAL TRANSITION; DIABETES MELLITUS; DOSE RESPONSE; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; MEAN ARTERIAL PRESSURE; NERVE STIMULATION; NONHUMAN; PENIS ERECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE RELAXATION; TESTOSTERONE BLOOD LEVEL; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; MUSCLE RELAXATION; PENIS;

AGING; ANIMALS; DIABETES MELLITUS; ENZYME INHIBITORS; ERECTILE DYSFUNCTION; HUMANS; HYPERTENSION; MALE; MOLECULAR TARGETED THERAPY; MUSCLE RELAXATION; NITRIC OXIDE; PENIS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION;

EID: 84927575395     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2014.278     Document Type: Review

References (65)

1. Foster, S. A., Annunziata, K., Shortridge, E. F., Freedman, D. & Viktrup, L. Erectile dysfunction with or without coexisting benign prostatic hyperplasia in the general US population: analysis of US National Health and Wellness Survey. Curr. Med. Res. Opin. http://dx.doi.org/10.1185/03007995.2013.837385.
2. Dean, R. C. & Lue, T. F. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol. Clin. North Am. 32, 379-395 (2005).
3. Feldman, H. A., Goldstein, I., Hatzichristou, D. G., Krane, R. J. & McKinlay, J. B. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J. Urol. 151, 54-61 (1994).
4. Yao, F. et al. Erectile dysfunction may be the first clinical sign of insulin resistance and endothelial dysfunction in young men. Clin. Res. Cardiol. 102, 645-651 (2013).
5. Behr-Roussel, D. et al. Erectile dysfunction: an early marker for hypertension? A longitudinal study in spontaneously hypertensive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288, R276-R283 (2005).
6. Akingba, A. G. & Burnett, A. L. Endothelial nitric oxide synthase protein expression, localization, and activity in the penis of the alloxan-induced diabetic rat. Mol. Urol. 5, 189-197 (2001).
7. Ignarro, L. J. et al. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem. Biophys. Res. Commun. 170, 843-850 (1990).
8. Burnett, A. L. et al. Immunohistochemical localization of nitric oxide synthase in the autonomic innervation of the human penis. J. Urol. 150, 73-76 (1993).
9. Bivalacqua, T. J., Usta, M. F., Champion, H. C., Kadowitz, P. J. & Hellstrom, W. J. Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease. J. Androl. 24, S17-S37 (2003).
10. Chitaley, K. & Webb, R. C. Nitric oxide induces dilation of rat aorta via inhibition of rho-kinase signaling. Hypertension 39, 438-442 (2002).
11. Lin, C.-S., Xin, Z.-C., Wang, Z., Lin, G. & Lue, T. F. Molecular Yin and Yang of erectile function and dysfunction. Asian J. Androl. 10, 433-440 (2008).
12. Kamm, K. E. & Stull, J. T. The function of myosin and myosin light chain kinase phosphorylation in smooth muscle. Annu. Rev. Pharmacol. Toxicol. 25, 593-620 (1985).
13. Reilly, C. M., Lewis, R. W., Stopper, V. S. & Mills, T. M. Androgenic maintenance of the rat erectile response via a non-nitric-oxide-dependent pathway. J. Androl. 18, 588-594 (1997).
14. Ming, X.-F. et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol. Cell. Biol. 22, 8467-8477 (2002).
15. Küthe, A. et al. Expression of different phosphodiesterase genes in human cavernous smooth muscle. J. Urol. 165, 280-283 (2001).
16. DeFeo, T. T. & Morgan, K. G. Calcium-force relationships as detected with aequorin in two different vascular smooth muscles of the ferret. J. Physiol. 369, 269-282 (1985).
17. Kimura, K. et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 273, 245-248 (1996).
18. Rembold, C. M. Regulation of contraction and relaxation in arterial smooth muscle. Hypertension 20, 129-137 (1992).
19. Sasaki, T., Kato, M. & Takai, Y. Consequences of weak interaction of rho GDI with the GTP-bound forms of rho p21 and rac p21. J. Biol. Chem. 268, 23959-23963 (1993).
20. Narumiya, S. The small GTPase Rho: cellular functions and signal transduction. J. Biochem. 120, 215-228 (1996).
21. Jin, L. & Burnett, A. L. RhoA/Rho-kinase in erectile tissue: mechanisms of disease and therapeutic insights. Clin. Sci. (Lond.) 110, 153-165 (2006).
22. Amano, M., Fukata, Y. & Kaibuchi, K. Regulation and functions of Rho-associated kinase. Exp. Cell Res. 261, 44-51 (2000).
23. Bivalacqua, T. J. et al. Attenuated RhoA/Rho-kinase signaling in penis of transgenic sickle cell mice. Urology 76, 510.e7-510.e12 (2010).
24. Hannan, J. L. et al. Inhibition of Rho-kinase improves erectile function, increases nitric oxide signaling and decreases penile apoptosis in a rat model of cavernous nerve injury. J. Urol. 189, 1155-1161 (2013).
25. Cho, S. Y., Park, K., Paick, J.-S. & Kim, S. W. Change of erectile function and responsiveness to phosphodiesterase type 5 inhibitors at different stages of streptozotocin-induced diabetes in rats. J. Sex. Med. 8, 1352-1361 (2011).
26. Vignozzi, L. et al. Testosterone regulates RhoA/Rho-kinase signaling in two distinct animal models of chemical diabetes. J. Sex. Med. 4, 620-630 (2007).
27. Chiou, W.-F., Liu, H.-K. & Juan, C.-W. Abnormal protein expression in the corpus cavernosum impairs erectile function in type 2 diabetes. BJU Int. 105, 674-680 (2010).
28. Breitenlechner, C. et al. Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P. Structure 11, 1595-1607 (2003).
29. Priviero, F. B., Jin, L.-M., Ying, Z., Teixeira, C. E. & Webb, R. C. Up-regulation of the RhoA/Rho-kinase signaling pathway in corpus cavernosum from endothelial nitric-oxide synthase (NOS), but not neuronal NOS, null mice. J. Pharmacol. Exp. Ther. 333, 184-192 (2010).
30. Wang, H., Eto, M., Steers, W. D., Somlyo, A. P. & Somlyo, A. V. RhoA-mediated Ca2+ sensitization in erectile function. J. Biol. Chem. 277, 30614-30621 (2002).
31. Chitaley, K. et al. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat. Med. 7, 119-122 (2001).
32. Uehata, M. et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389, 990-994 (1997).
33. Moody, J. A., Vernet, D., Laidlaw, S., Rajfer, J. & Gonzalez-Cadavid, N. F. Effects of long-term oral administration of L-arginine on the rat erectile response. J. Urol. 158, 942-947 (1997).
34. Sawada, N. et al. cGMP-dependent protein kinase phosphorylates and inactivates RhoA. Biochem. Biophys. Res. Commun. 280, 798-805 (2001).
35. Sauzeau, V. et al. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. J. Biol. Chem. 275, 21722-21729 (2000).
36. Carter, R. W., Begaye, M. & Kanagy, N. L. Acute and chronic NOS inhibition enhances alpha(2)- adrenoreceptor-stimulated RhoA and Rho kinase in rat aorta. Am. J. Physiol. Heart Circ. Physiol. 283, H1361-H1369 (2002).
37. Sauzeau, V., Rolli-Derkinderen, M., Marionneau, C., Loirand, G. & Pacaud, P. RhoA expression is controlled by nitric oxide through cGMP-dependent protein kinase activation. J. Biol. Chem. 278, 9472-9480 (2003).
38. Sugimoto, M. et al. Rho-kinase phosphorylates eNOS at threonine 495 in endothelial cells. Biochem. Biophys. Res. Commun. 361, 462-467 (2007).
39. Mita, S., Kobayashi, N., Yoshida, K., Nakano, S. & Matsuoka, H. Cardioprotective mechanisms of Rho-kinase inhibition associated with eNOS and oxidative stress-LOX-1 pathway in Dahl salt-sensitive hypertensive rats. J. Hypertens. 23, 87-96 (2005).
40. Laufs, U. & Liao, J. K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273, 24266-24271 (1998).
41. Saito, M. et al. Hydroxyfasudil ameliorates penile dysfunction in the male spontaneously hypertensive rat. Pharmacol. Res. 66, 325-331 (2012).
42. Burchardt, M. et al. Hypertension is associated with severe erectile dysfunction. J. Urol. 164, 1188-1191 (2000).
43. Wilkes, N., White, S., Stein, P., Bernie, J. & Rajasekaran, M. Phosphodiesterase-5 inhibition synergizes rho-kinase antagonism and enhances erectile response in male hypertensive rats. Int. J. Impot. Res. 16, 187-194 (2004).
44. Chitaley, K., Webb, R. C., Dorrance, A. M. & Mills, T. M. Decreased penile erection in DOCA-salt and stroke prone-spontaneously hypertensive rats. Int. J. Impot. Res. 13 (Suppl. 5), S16-S20 (2001).
45. Lasker, G. F. et al. The selective Rho-kinase inhibitor azaindole-1 has long-lasting erectile activity in the rat. Urology 81, 465.e7-465.e14 (2013).
46. Pankey, E. A. et al. The Rho kinase inhibitor azaindole-1 has long-acting vasodilator activity in the pulmonary vascular bed of the intact chest rat. Can. J. Physiol. Pharmacol. 90, 825-835 (2012).
47. Guagnini, F., Ferazzini, M., Grasso, M., Blanco, S. & Croci, T. Erectile properties of the Rho-kinase inhibitor SAR407899 in diabetic animals and human isolated corpora cavernosa. J. Transl. Med. 10, 59 (2012).
48. Bivalacqua, T. J. et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc. Natl Acad. Sci. USA 101, 9121-9126 (2004).
49. Bivalacqua, T. J., Hellstrom, W. J., Kadowitz, P. J. & Champion, H. C. Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic-associated erectile dysfunction. Biochem. Biophys. Res. Commun. 283, 923-927 (2001).
50. Musicki, B. & Burnett, A. L. Endothelial dysfunction in diabetic erectile dysfunction. Int. J. Impot. Res. 19, 129-138 (2007).
51. Costa, C. et al. Increased endothelial apoptotic cell density in human diabetic erectile tissue-comparison with clinical data. J. Sex. Med. 6, 826-835 (2009).
52. Chang, J. et al. Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis. Proc. Natl Acad. Sci. USA 103, 14495-14500 (2006).
53. Li, W. J., Park, K., Paick, J.-S. & Kim, S. W. Chronic treatment with an oral rho-kinase inhibitor restores erectile function by suppressing corporal apoptosis in diabetic rats. J. Sex. Med. 8, 400-410 (2011).
54. Morelli, A. et al. Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signaling hyperactivation. J. Sex. Med. 6, 91-106 (2009).
55. Toque, H. A. et al. Activated Rho kinase mediates diabetes-induced elevation of vascular arginase activation and contributes to impaired corpora cavernosa relaxation: possible involvement of p38 MAPK activation. J. Sex. Med. 10, 1502-1515 (2013).
56. Sezen, S. F., Lagoda, G., Musicki, B. & Burnett, A. L. Hydroxyl Fasudil, an inhibitor of Rho signaling, improves erectile function in diabetic rats: a role for neuronal ROCK. J. Sex. Med. 11, 2164-2171 (2014).
57. Park, K., Kim, S. W., Rhu, K. S. & Paick, J.-S. Chronic administration of an oral Rho kinase inhibitor prevents the development of vasculogenic erectile dysfunction in a rat model. J. Sex. Med. 3, 996-1003 (2006).
58. Jin, L. et al. Elevated RhoA/Rho-kinase activity in the aged rat penis: mechanism for age-associated erectile dysfunction. FASEB J. 20, 536-538 (2006).
59. Johannes, C. B. et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J. Urol. 163, 460-463 (2000).
60. Rajasekaran, M., White, S., Baquir, A. & Wilkes, N. Rho-kinase inhibition improves erectile function in aging male Brown-Norway rats. J. Androl. 26, 182-188 (2005).
61. Magheli, A. & Burnett, A. L. Erectile dysfunction following prostatectomy: prevention and treatment. Nat. Rev. Urol. 6, 415-427 (2009).
62. Hatzimouratidis, K. et al. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur. Urol. 55, 334-347 (2009).
63. Pavlovich, C. P. et al. Nightly vs on-demand sildenafil for penile rehabilitation after minimally invasive nerve-sparing radical prostatectomy: results of a randomized double-blind trial with placebo. BJU Int. 112, 844-851 (2013).
64. Gratzke, C. et al. Activated RhoA/Rho kinase impairs erectile function after cavernous nerve injury in rats. J. Urol. 184, 2197-2204 (2010).
65. Löhn, M. et al. Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor. Hypertension 54, 676-683 (2009).